Clinical trial design for adenoviral gene therapy products

Drug News and Perspectives

Volumn 22, Issue 3, 2009, Pages 140-145

  Shirakawa, Toshiro ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADVEXIN; ANTINEOPLASTIC AGENT; CEREPRO; CISPLATIN; FLUOROURACIL; GANCICLOVIR; GENDICINE; H 101; METHOTREXATE; ONCOLYTIC ADENOVIRUS; ONYX 015; PROTEIN P53; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

ADENOVIRUS; ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GLIOBLASTOMA; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; NONHUMAN; PROSTATE CANCER; REVIEW; VIRUS CAPSID; VIRUS GENOME; VIRUS REPLICATION;

ADENOVIRIDAE; CLINICAL TRIALS AS TOPIC; DEFECTIVE VIRUSES; GENE THERAPY; GENETIC VECTORS; GENOME, VIRAL; HUMANS; NEOPLASMS;

EID: 67449101064     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2009.22.3.1354090     Document Type: Review

References (60)

1. Edelstein, M.L., Abedi, M.R. and Wixon, J. Gene therapy clinical trials worldwide to 2007 - an update. J Gene Med 2007, 9(10): 833-842
2. Campos, S.K. and Barry, M.A. Current advances and future challenges in Adenoviral vector biology and targeting. Curr Gene Ther 2007, 7(3): 189-204.
3. Volpers, C. and Kochanek, S. Adenoviral vectors for gene transfer and therapy. J Gene Med 2004, 6 Suppl 1: S164-71.
4. Vattemi, E. and Claudio, P.P. Adenoviral gene therapy in head and neck cancer. Drug News Perspect 2006, 19(6): 329-337
5. Flotte, T.R. Gene therapy: the first two decades and the current state-of-the-art. J Cell Physiol 2007, 213(2): 301-305
6. Raper, S.E., Chirmule, N., Lee, F.S. et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003, 80(1-2): 148-158
7. Lusky, M. Good manufacturing practice production of adenoviral vectors for clinical trials. Hum Gene Ther 2005, 16(3): 281-291
8. Peng, Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005, 16(9): 1016-1027 (Pubitemid 41324561)
9. Yu, W. and Fang, H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007, 7(2): 141-148
10. Immonen, A., Vapalahti, M., Tyynela, K. et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol Ther 2004, 10(5): 967-972
11. Carmen, I.H. A death in the laboratory: the politics of the Gelsinger aftermath. Mol Ther 2001, 3(4): 425-428
12. Tanne, J.H. US gene therapy trial is to restart, despite patient's death. BMJ 2007, 335(7631): 1172-1173
13. Kaiser, J. Clinical trials. Gene transfer an unlikely contributor to patient's death. Science 2007, 318(5856): 1535.
14. Scharschmidt, T. and Lo, B. Clinical trial design issues raised during recombinant DNA advisory committee review of gene transfer protocols. Hum Gene Ther 2006, 17(4): 448-54.
15. Cornetta, K. and Smith, F.O. Regulatory issues for clinical gene therapy trials. Hum Gene Ther 2002, 13(10): 1143-1149
16. Muruve, D.A. The innate immune response to adenovirus vectors. Hum Gene Ther 2004, 15(12): 1157-1166
17. Rowe, W.P., Huebner, R.J., Gilmore, L.K., Parrott, R.H. and Ward, T.G. Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc Soc Exp Biol Med 1953, 84(3): 570-573
18. Russell, W.C. Update on adenovirus and its vectors. J Gen Virol 2000, 81(Pt 11): 2573-2604
19. Smith, T.A., Idamakanti, N., Rollence, M.L. et al. Adenovirus serotype 5 fiber shaft influences in vivo gene transfer in mice. Hum Gene Ther 2003, 14(8): 777-787
20. Shayakhmetov, D.M., Gaggar, A., Ni, S., Li, Z.Y. and Lieber, A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005, 79(12): 7478-7491 (Pubitemid 40756784)
21. Shayakhmetov, D.M., Li, Z.Y., Ni, S. and Lieber, A. Analysis of adenovirus sequestration in the liver, transduction of hepatic cells, and innate toxicity after injection of fiber-modified vectors. J Virol 2004, 78(10): 5368-5381
22. Alemany, R., Suzuki, K. and Curiel, D.T. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000, 81(Pt 11): 2605-2609
23. Bernt, K.M., Ni, S., Gaggar, A., Li, Z.Y., Shayakhmetov, D.M. and Lieber, A. The effect of sequestration by nontarget tissues on anti-tumor efficacy of systemically applied, conditionally replicating adenovirus vectors. Mol Ther 2003, 8(5): 746-755 (Pubitemid 37527449)
24. Stone, D., Liu, Y., Shayakhmetov, D., Li, Z.Y., Ni, S. and Lieber, A. Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver. J Virol 2007, 81(9): 4866-4871
25. Weitzman, M.D. and Ornelles, D.A. Inactivating intracellular antiviral responses during adenovirus infection. Oncogene 2005, 24(52): 7686-7696
26. Cuconati, A. and White, E. Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. Genes Dev 2002, 16(19): 2465-78.
27. Dobner, T. and Kzhyshkowska, J. Nuclear export of adenovirus RNA. Curr Top Microbiol Immunol 2001, 259: 25-54.
28. Flint, S.J. and Gonzalez, R.A. Regulation of mRNA production by the adenoviral E1B 55-kDa and E4 Orf6 proteins. Curr Top Microbiol Immunol 2003, 272: 287-330.
29. Lonberg-Holm, K. and Philipson, L. Early events of virus-cell interaction in an adenovirus system. J Virol 1969, 4(4): 323-338
30. Lieber, A., He, C.Y., Meuse, L. et al. The role of Kupffer cell activation and viral gene expression in early liver toxicity after infusion of recombinant adenovirus vectors. J Virol 1997, 71(11): 8798-8807
31. Liu, Q., Zaiss, A.K., Colarusso, P. et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 2003, 14(7): 627-643
32. Mizuguchi, H. and Hayakawa, T. Targeted adenovirus vectors. Hum Gene Ther 2004, 15(11): 1034-1044
33. Molnar-Kimber, K.L., Sterman, D.H., Chang, M. et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum Gene Ther 1998, 9(14): 2121-2133
34. Sakhuja, K., Reddy, P.S., Ganesh, S. et al. Optimization of the generation and propagation of gutless adenoviral vectors. Hum Gene Ther 2003, 14(3): 243-254
35. Graham, F.L., Smiley, J., Russell, W.C. and Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 1977, 36(1): 59-74.
36. Fallaux, F.J., Bout, A., van der Velde, I. et al. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 1998, 9(13): 1909-1917
37. Schiedner, G., Hertel, S. and Kochanek, S. Efficient transformation of primary human amniocytes by E1 functions of Ad5: generation of new cell lines for adenoviral vector production. Hum Gene Ther 2000, 11(15): 2105-2116 (Pubitemid 30778413)
38. Biederer, C., Ries, S., Brandts, C.H. and McCormick, F. Replication-selective viruses for cancer therapy. J Mol Med 2002, 80(3): 163-75.
39. Vaha-Koskela, M.J., Heikkila, J.E. and Hinkkanen, A.E. Oncolytic viruses in cancer therapy. Cancer Lett 2007, 254(2): 178-216.
40. Freytag, S.O., Movsas, B., Aref, I. et al. Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. Mol Ther 2007, 15(5): 1016-1023
41. Ganly, I., Kirn, D., Eckhardt, G. et al. A phase I study of Onyx-015, an EIB attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 2000, 6(3): 798-806.
42. Lamfers, M.L., Grill, J., Dirven, C.M. et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res 2002, 62(20): 5736-5742
43. Shirakawa, T., Hamada, K., Zhang, Z. et al. A cox-2 promoter-based replication-selective adenoviral vector to target the cox-2-expressing human bladder cancer cells. Clin Cancer Res 2004, 10(13): 4342-4348
44. Kreppel, F. and Kochanek, S. Modification of adenovirus gene transfer vectors with synthetic polymers: a scientific review and technical guide. Mol Ther 2008, 16(1): 16-29.
45. Power, A.T. and Bell, J.C. Cell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancer. Mol Ther 2007, 15(4): 660-665 (Pubitemid 46431985)
46. Komarova, S., Kawakami, Y., Stoff-Khalili, M.A., Curiel, D.T. and Pereboeva, L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther 2006, 5(3): 755-766
47. Hamada, K., Desaki, J., Nakagawa, K. et al. Carrier cell-mediated delivery of a replication-competent adenovirus for cancer gene therapy. Mol Ther 2007, 15(6): 1121-1128 (Pubitemid 46813615)
48. Crystal, R.G., McElvaney, N.G., Rosenfeld, M.A. et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis. Nat Genet 1994, 8(1): 42-51. (Pubitemid 2122259)
49. Clayman, G.L., el-Naggar, A.K., Lippman, S.M. et al. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J Clin Oncol 1998, 16(6): 2221-2232
50. Nemunaitis, J., Swisher, S.G., Timmons, T. et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol 2000, 18(3): 609-622 (Pubitemid 30078542)
51. Guo, J. and Xin, H. Chinese gene therapy. Splicing out the West? Science 2006, 314(5803): 1232-1235
52. Chada, S., Menander, K.B., Bocangel, D., Roth, J.A. and Ramesh, R. Cancer targeting using tumor suppressor genes. Front Biosci 2008, 13: 1959-1967
53. Huebner, R.J., Rowe, W.P., Schatten, W.E., Smith, R.R. and Thomas, L.B. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956, 9(6): 1211-1218
54. Freytag, S.O., Strieker, H., Pegg, J. et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res 2003, 63(21): 7497-7506
55. Lips, I.M., Dehnad, H., van Gils, C.H., Boeken Kruger, A.E., van der Heide, U.A. and van Vulpen, M. High-dose intensity-modulated radiotherapy for prostate cancer using daily fiducial marker-based position verification: acute and late toxicity in 331 patients. Radiat Oncol 2008, 3: 15.
56. Hatano, K., Araki, H., Sakai, M. et al. Current status of intensity-modulated radiation therapy (IMRT). Int J Clin Oncol 2007, 12(6): 408-415
57. Arcangeli, S., Saracino, B., Petrongari, M.G. et al. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area. Radiother Oncol 2007, 84(2): 148-155
58. Palmer, D.H., Young, L.S. and Mautner, V. Cancer gene-therapy: clinical trials. Trends Biotechnol 2006, 24(2): 76-82. (Pubitemid 43151979)
59. Zeimet, A.G. and Marth, C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 2003, 4(7): 415-422
60. Shirakawa, T., Terao, S., Hinata, N. et al. Long-term outcome of phase I/II clinical trial of Ad-OC-TK/VAL gene therapy for hormone-refractory metastatic prostate cancer. Hum Gene Ther 2007, 18(12): 1225-1232 (Pubitemid 350261965)